Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab- bas
Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe - Pharmaceutical Business review
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
What Happened To Puma Biotechnology?
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
Puma Biotechnology
Puma Biotechnology, Inc. 2020 Current Report 8-K
European Commission Grants Marketing Authorisation for Puma Biotechnology's NERLYNX® (neratinib) for Extended Adjuvant Treatm
Puma Biotech shares slide after glimpse of trial data on cancer drug | Financial Times
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
With EU Approval For Puma Biotech's Breast Cancer Drug Unlikely, Cowen Downgrades
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Puma Biotechnology
Puma Biotech gets EU panel nod for breast cancer drug, Health News, ET HealthWorld
PUMA Background
Is Puma Biotechnology Inc. late reporting EU clinical trials?
